CDNA
Caredx Inc

3,258
Mkt Cap
$803.38M
Volume
1.44M
52W High
$26.37
52W Low
$10.96
PE Ratio
13.10
CDNA Fundamentals
Price
$15.62
Prev Close
$15.01
Open
$14.96
50D MA
$14.53
Beta
1.37
Avg. Volume
1.02M
EPS (Annual)
$0.9281
P/B
2.58
Rev/Employee
$513,515.39
Loading...
Loading...
News
all
press releases
CareDx (NASDAQ:CDNA) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded shares of CareDx from a "sell" rating to a "buy" rating in a research note on Saturday...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CareDx, Inc. (Nasdaq: CDNA) The Transplant Company a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value...
Business Wire·2d ago
News Placeholder
CareDx (NASDAQ:CDNA) Given New $25.00 Price Target at BTIG Research
BTIG Research raised their price objective on CareDx from $22.00 to $25.00 and gave the stock a "buy" rating in a research note on Thursday...
MarketBeat·2d ago
News Placeholder
CareDx (NASDAQ:CDNA) Shares Gap Up - Here's Why
CareDx (NASDAQ:CDNA) Shares Gap Up - Here's Why...
MarketBeat·3d ago
News Placeholder
CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025
CareDx, Inc. (Nasdaq: CDNA) The Transplant Company a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value...
Business Wire·3d ago
News Placeholder
CareDx (CDNA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for CareDx (CDNA) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·4d ago
News Placeholder
CareDx (CDNA) Surpasses Q3 Earnings and Revenue Estimates
CareDx (CDNA) delivered earnings and revenue surprises of +115.38% and +5.07%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
News Placeholder
CareDx Announces Third Quarter 2025 Financial Results
CareDx, Inc. (Nasdaq: CDNA) The Transplant Company a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare...
Business Wire·5d ago
News Placeholder
CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer
CareDx, Inc. (Nasdaq: CDNA), The Transplant Company a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value...
Business Wire·13d ago
News Placeholder
CareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the American College of Cardiology: Heart Failure
CareDx, Inc. (Nasdaq: CDNA) a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for...
Business Wire·17d ago

Latest CDNA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.